Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the Bite: Tick Salivary Proteins Targeting Hemostasis and Inflammation; Implications for Cardiovascular Disease.

Thrombosis and haemostasis·2026
Same author

Structural determinants of beta-cell failure in type 2 diabetes: a multimodality imaging study.

Metabolism: clinical and experimental·2026
Same author

Sex Differences in [ <sup>68</sup>Ga]Ga-NODAGA-Exendin-4 Uptake in the Pituitary of Individuals With Type 2 Diabetes.

Diabetes, obesity & metabolism·2026
Same author

Clinical presentation and outcomes of medullary thyroid cancer in two European countries: impact of diagnostic strategies.

European thyroid journal·2026
Same author

Beta cell function and mass in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass.

Diabetologia·2026
Same author

68 Ga-NODAGA-EXENDIN-4 PET/CT in the Detection or the Exclusion of Occult Sporadic Insulinomas.

Clinical nuclear medicine·2025

Related Experiment Video

Updated: Jul 11, 2026

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Development and application of peptide-based radiopharmaceuticals.

Ingrid Dijkgraaf1, Otto C Boerman, Wim J G Oyen

  • 1Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Anti-Cancer Agents in Medicinal Chemistry
|September 28, 2007
PubMed
Summary

Radiolabeled receptor-binding peptides are crucial radiopharmaceuticals for tumor diagnosis and therapy. These peptides target specific receptors, enabling precise imaging and treatment of cancers.

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Experiment Videos

Last Updated: Jul 11, 2026

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Area of Science:

  • Nuclear Medicine
  • Radiopharmaceutical Chemistry
  • Oncology

Background:

  • Radiolabeled receptor-binding peptides are a key class of radiopharmaceuticals for tumor diagnosis and therapy.
  • The specific receptor binding of ligands is leveraged by labeling them with radionuclides to target tissues expressing particular receptors.
  • This concept has driven significant research in nuclear medicine for in vivo targeting of receptor-expressing tissues.

Purpose of the Study:

  • To provide an overview of radiolabeled peptides for tumor diagnosis and therapy.
  • To discuss criteria for peptide ligand development, radioisotope selection, and labeling methods.
  • To review the current clinical applications of radiopeptides in oncology.

Main Methods:

  • Review of existing literature on radiolabeled peptides.
  • Discussion of peptide ligand design and radioisotope selection criteria.
  • Analysis of labeling techniques and chemical synthesis of radiopeptides.

Main Results:

  • Peptide-receptor radionuclide imaging (PRRI) uses gamma emitters for visualization.
  • Peptide-receptor radionuclide therapy (PRRT) utilizes beta emitters for targeted irradiation.
  • Octreotide is a successful example for neuroendocrine tumor imaging and therapy; other peptides are in development.

Conclusions:

  • Radiolabeled peptides offer versatile tools for both diagnosing and treating tumors.
  • Ongoing research and clinical trials are expanding the utility of various radiopeptides.
  • The development of novel radiopeptides holds significant promise for personalized cancer management.